Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00

Definium Therapeutics (NASDAQ:DFTX) had its price target raised by JonesTrading from $74.00 to $90.00 in a research note published on Thursday,Benzinga reports. JonesTrading currently has a buy rating on the stock.

DFTX has been the topic of a number of other reports. Canaccord Genuity Group set a $64.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. Royal Bank Of Canada raised their target price on shares of Definium Therapeutics from $57.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday. Oppenheimer restated an “outperform” rating and set a $70.00 target price on shares of Definium Therapeutics in a report on Wednesday. Finally, Stifel Nicolaus upped their price target on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $62.14.

Definium Therapeutics Trading Down 2.9%

Shares of DFTX opened at $42.63 on Thursday. Definium Therapeutics has a 52-week low of $8.70 and a 52-week high of $49.70. The stock has a market cap of $5.73 billion, a PE ratio of -12.43 and a beta of 2.23. The firm’s fifty day moving average is $39.83 and its two-hundred day moving average is $26.82. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Research analysts forecast that Definium Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This represents a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 48,096 shares of company stock valued at $2,165,763 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Commodore Capital LP grew its position in Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after acquiring an additional 475,000 shares during the period. Orbimed Advisors LLC purchased a new stake in Definium Therapeutics in the third quarter valued at $4,337,000. Two Sigma Investments LP lifted its stake in shares of Definium Therapeutics by 424.9% in the 3rd quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after purchasing an additional 239,965 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Definium Therapeutics by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after purchasing an additional 198,878 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Definium Therapeutics by 62.6% in the 3rd quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock valued at $3,516,000 after purchasing an additional 114,805 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 VOYAGE study of DT120 ODT in generalized anxiety disorder achieved its primary goals. The treatment produced a 5.4-point improvement on the HAM-A anxiety scale versus placebo, strengthening the case for DT120’s potential efficacy and supporting future regulatory and commercial plans. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: The positive clinical readout has increased confidence in additional DT120 trials and potentially supports the drug’s use across more than one indication. Investors are also watching for a further catalyst expected in September 2026. Definium Therapeutics Hits Phase 3 GAD Goals For DT120 ODT
• Positive Sentiment: Analysts raised their targets following the data: JonesTrading increased its target to $90 from $74 and maintained a Buy rating; Robert W. Baird raised its target to $75 from $57; Wells Fargo lifted its target to $72 from $68; and RBC raised its target to $66 from $57 while assigning an Outperform rating. These revisions indicate substantial perceived upside, although targets are not guarantees. Analyst price-target updates
• Positive Sentiment: Needham reportedly expects DFTX shares to rise, while recent analyst commentary broadly reflects optimism about DT120’s development prospects. Needham analyst outlook
• Neutral Sentiment: Near-term trading may remain volatile as investors assess the Phase 3 results, upcoming milestones, and expectations for third-quarter earnings. HC Wainwright Q3 earnings estimate
• Negative Sentiment: DFTX remains an unprofitable biotechnology company, and its latest reported quarter missed consensus EPS estimates. The stock’s large recent rally and elevated volatility could also encourage profit-taking despite the favorable trial news.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.